Histoplasmosis in Africa: An emerging or a neglected disease?

1Inhalation of conidia of H. capsulatum leads to histoplasmosis in some people. Hcc is patchily distributed around the world, whereas Hcd is essentially restricted to Africa. Histoplasmosis was first described by Darling in the Canal Zone in Panama in 1906; patients were described as presenting with features suggestive of disseminated TB. The first case of Hcd was described in West Africa in 1943 by Duncan.

2The true global burden of histoplasmosis is not well documented despite its endemicity and not addressed previously for Africa. Histoplasmosis is not a notifiable disease, thus hard data on the incidence and prevalence, as well as information on its morbidity and mortality, are fragmentary or not available in many endemic areas. Recently, WHO broadened their list of core neglected tropical diseases (NTDs) to include deep mycoses, of which histoplasmosis is one. The greatest attributable risk factor for histoplasmosis is the spread of HIV, although immunosuppressive agents used in transplant patients or chronic inflammatory diseases also contribute to its increase. Disseminated histoplasmosis was classified as an AIDS-defining infection in 1987.

3During highly active antiretroviral therapy (HAART), morbidity and mortality due to histoplasmosis remain a public health problem in low- and middle-income countries (LMICs). Primary infection is extremely common in highly endemic areas based on the prevalence of skin test reactivity, with 23% to 81% and 5% to 50% of the population testing positive in Guatemala and Mexico, respectively. In these areas, progressive disseminated histoplasmosis (PDH) can occur in 5% to 20% of patients infected with HIV. However, in immunocompetent persons, it is mostly asymptomatic or spontaneously self-limiting.

4Histoplasmosis is highly prevalent in areas along the Mississippi and Ohio valleys in the United States and in Central and South America. It is also endemic in India and Southeast Asia. In Africa, the most predominant infective agent is Hcc, which can coexist with Hcd. Hcd is primarily found in Central and West Africa and Madagascar, and histoplasmosis caused by this fungus is often referred to as African histoplasmosis, which is a misnomer because African patients can be infected with both variants. Though not endemic in Europe, reports of microfoci of histoplasmosis due to Hcc have been reported in Italy.

5In the African continent, there are limited incidence cohort data on histoplasmosis despite the burden of HIV disease in sub-Saharan Africa. Surveys of histoplasmin (a mycelial-phase exo-antigen) cutaneous sensitivity have shown that the rate of positive reactors ranges from 0.0% to 28%, with cross reactivity being demonstrated between Hcc and Hcd in Nigeria. In Nigeria, a higher prevalence of skin test reactivity (approximately 35%) was found in rural populations, especially among farmers, local traders, and cave guides.

6This review seeks to highlight knowledge gaps regarding the epidemiological, diagnostic (clinical and laboratory), and therapeutic aspects of histoplasmosis in HIV-infected and non–HIV-infected patients in Africa.

7Literature searches for publications on histoplasmosis in Africans preceding 30 March 2017, were performed using PubMed, Web of Science, Google Scholar, Cochrane Library, African Journals Online (AJOL), Africa-Wide: NiPAD, CINAHL (accessed via EBSCO Host) databases, and grey literature to identify all published papers regarding the topic. Articles published in other languages (e.g., French, German, and Portuguese) were considered if they were cited in any of the databases searched. The main search comprised individual searches using detailed medical subject heading (MeSH) terms for histoplasmosis, Africa (also the names of the 54 African countries), and HIV/AIDS combined with terms relevant to histoplasmosis, including broad terms such as ‘diagnosis’ and ‘management’. The Boolean operator ‘AND’ and ‘OR’ were used to combine and narrow the searches. Only reports with patients’ country of origin identified were included. The references in all relevant papers were reviewed for additional publications that may not have been cited elsewhere (‘snow balling’), as well as our own paper files. We did not systematically search all meeting abstracts and other ‘grey literature’, primarily because only a very limited number of scientific conferences related to mycological topics have been held in Africa.

8The case definitions employed were based on an international consensus statement by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (EORTC/IFICG) and the Mycoses Study Group (MSG).

9Historically, H. capsulatum was considered to be divided into three ‘varieties’ on the basis of morphologic characteristics, as follows: Hcc, prevalent in the Americas; Hcd, mostly reported in Central and Western Africa; and H. capsulatum var. farciminosum, which causes epizootic lymphangitis in horses and is isolated from equines in North Africa and the Middle East. The environmental mould phase (saprophytic form) may form macroconidia and microconidia. Microconidia are smooth-walled with a diameter of 2 to 4 μm and are the infectious elements acquired by inhalation. The yeast phase (parasitic form) develops as oval budding cells with a diameter of 2 to 4 μm, predominantly observed within macrophages and histiocytes, indicative of persistent latency. Hcd yeast forms are larger—8 to 15 μm—with thicker walls, and this differentiation is sufficient for definitive diagnosis. There are other fungi that can be mistaken for H. capsulatum, for example, Emmonsia spp.

10Prior to the HAART era, subclinical or symptomatic histoplasmosis occurred in 12/100 person-years at risk in a cohort of HIV-infected patients in the US. The introduction of effective ART has not led to a significant reduction in the incidence of histoplasmosis in HIV-infected patients. No such study has been replicated in Africa.

11Gugnani and colleagues reported a histoplasmin skin sensitivity prevalence of 3.5% and 3.0% in the community and 8.9% and 6.5% in hospitalised individuals for Hcc and Hcd, respectively, in Nigeria. In Eastern Nigeria, a natural reservoir of Hcd was discovered in the soil of caves mixed with bat guano. There were 20 cases of Hcd infection documented in an outbreak amongst cave explorers in Nigeria. Environmental exposure to nitrogen-rich guano soil has been shown to increase the risk of histoplasmosis in the general populace. A landmark study analyzing employment and Histoplasma exposure in Uganda in the pre-AIDS era showed that those reactive to histoplasmin were mostly sawmill workers. A past history of cave exploration; presence at and/or participation in excavation sites; woodcutting; and exposure to bird roosts, farms, or poultry have also been documented. In a case-controlled study involving HIV-infected patients with histoplasmosis compared to controls without histoplasmosis, a strong association between histoplasmosis and contact with chicken coops was reported. Skin-test surveys using histoplasmin showed some exposure throughout Central America and parts of South America as well as Puerto Rico, Dominica, and Mexico in addition to the central US with almost no skin-test sensitivity positivity in Europe apart from Italy and France.

12Histoplasmosis—including both Hcd and Hcc—has been reported from 32 countries in Africa (Table 1). While Hcc occurs predominantly in Southern and North Africa, Hcd is found primarily in Central and Western Africa. In addition, there have also been five documented cases described from Madagascar (Fig 1). This map shows the distribution of the reported cases across Africa and not necessarily the true distribution of the burden of the problem. Some African countries lack the skilled personnel and facilities to make the diagnosis, and the number of reported cases is likely to be an underestimation because of the fact that there are few skilled personnel and facilities in many areas.

13Our exhaustive literature search revealed a total of 470 documented cases of histoplasmosis reported from the African continent (Table 1) dating from 1952 to 2017 (see S1 Table). Hcd accounted for 247 reported cases and Hcc for 185 reported cases, with some only documented serologically. It is noteworthy that a significant number of the histoplasmosis cases in Africa were reported prior to the outbreak of the HIV pandemic. Hcd was the causative organism in osteolytic lesions in HIV-negative children (S1 Table). HIV coinfection was reported predominantly in Hcc and in adults. In contrast to Hcc, HIV and Hcd coinfection was initially thought to be rare in Africans. This was most likely due to a problem of underreporting or under-recognition because recent reports have refuted this; our literature search revealed over 25 reported cases (S1 Table).

14The distribution of the disease across Africa (Fig 1) is far from uniform; Hcd was predominantly reported in West, Central, and East Africa. The majority of the reports of Hcc were in the southern part of Africa; however, Egypt and Morocco were the only two countries in Northern Africa with reports of human histoplasmosis caused by Hcc. It is possible that some of the Hcc cases in South Africa might have been Emergomyces africanus, which is endemic in Southern Africa. Some apparent microfoci of Hcc are reported from the Democratic Republic of Congo (DRC), Ghana, Kenya, Ivory Coast, Benin, and Senegal. Perhaps these cases are due to the mobility and/or emigration of persons in these regions, but probably some microfoci exist. The explanation for the variability and patchy nature of the disease distribution is not clear and could possibly relate to climatic factors, bird migration, and/or contact with bat colonies.

15The majority (287 out of 470 [61%]) of the reported cases were in HIV-negative patients. While Hcd accounted for 247 such cases, most were in patients who were immunocompetent (Table 1), and a significant proportion presented as localised cutaneous and/or bone lesions. However, a significant minority presented as disseminated histoplasmosis in AIDS patients. This is consistent with existing data from HIV-infected patients, among which 95% of cases involve disseminated histoplasmosis and 90% of cases involve patients with CD4 counts below 200/mm3. In Southern Africa, there were 119 cases of Hcc diagnosed, with 80% (95) in HIV-infected patients, which is in keeping with a report from Europe that demonstrated the strong relationship between HIV and Hcc coinfection; histoplasmosis was the AIDS-defining disease in nearly 61% of patients in a review of histoplasmosis in Europe.

16Of the 470 histoplasmosis cases, West Africa had the highest number of cases (179 [38%]) followed by Southern Africa (150 [32%]), while Northern Africa had the fewest documented cases (18) (Fig 1). In contrast, there are several cases of equine histoplasmosis from Northern Africa. Nigeria had the highest number of reported cases (124 cases) (Table 1). Most cases presented as cutaneous and bone lesions, with only four cases of disseminated Hcd histoplasmosis, which were all HIV-positive patients. These four patients were Nigerian émigrés in the Western world and Saudi Arabia. Nigeria has the second highest number of people living with HIV infection in Africa, an estimated three million. Interestingly, in several of the case reports from Nigeria, patients were first misdiagnosed as malignancies until the histology report showed otherwise. In contrast, South Africa reported only Hcc cases, with almost an even distribution between HIV-positive and -negative patients. Zimbabwe, which shares a border with South Africa, had 57 histoplasmosis cases reported in one series, all Hcc apart from one Hcd case.

17While Hcc typically presents as an acute respiratory or febrile picture, Hcd rarely manifests as pulmonary disease but more commonly as a subacute infection of skin, lymph nodes, subcutaneous (abscesses), and bone lesions. Disease manifestations vary depending on immune status and the number of fungal particles inhaled. Most cases of acute histoplasmosis in immunocompetent individuals tend to resolve spontaneously. In immunocompromised patients, histoplasmosis accounts for significant morbidity and mortality.

18A large case series (56 patients) by Cockshott and Lucas gave a detailed clinical presentation of Hcd infection. Cutaneous, subcutaneous, and bone lesions were the most common clinical presentations of this infection and can be localised or disseminated. Cutaneous histoplasmosis is considered to be from haematogenous spread, although occasionally primary inoculation of the skin has been documented. In a series of ‘African histoplasmosis’ patients from Mali, 62% presented with skin diseases, 46% with lymphadenopathy, 21% with bone lesions, 26% with gut disease, and 4% with infection of the lungs. The report of 72 patients with AIDS from Europe revealed skin manifestations in 47.2% of all cases; among the 27 cases acquired from Africa—of which seven were cases of Hcd—skin manifestations were seen in 44%. Localised cutaneous Hcd is seen most predominantly in the immunocompetent individual, while disseminated Hcd is seen in the immunosuppressed. However, disseminated cutaneous disease has been documented in immunocompetent individuals infected with African histoplasmosis in Africans and non-Africans. The spectrum of cutaneous eruption includes polymorphic plaques, papules, pustules, nodules, ulcers, molluscum-like lesions, acneiform eruptions, exfoliative erythroderma, abscesses, and cellulitis irrespective of the immune status.

19Gastrointestinal histoplasmosis from Hcd has been reported in disseminated disease and the progressive disseminated form. It was found to be more common in the setting of HIV in the review by Loulergue and colleagues. Clinical features include abdominal pain, hematemesis, diarrhoea, dysphagia from peritonitis, gastrointestinal bleeding, and intestinal pathologies such as ulceration and perforation. Table 2 summarises the presentation of histoplasmosis in Africans.

20TB is the closest mimic of histoplasmosis, and limited access to diagnostic facilities may be responsible for some misdiagnoses. Similar to pulmonary TB, chronic pulmonary histoplasmosis (usually Hcc) starts with malaise, fever, fatigue, cough, and sputum. However, sputum production, weight loss, and night sweat are less prominent than TB. Eventually, chronic pulmonary histoplasmosis often results in pulmonary insufficiency and cor pulmonale. It rarely causes death if untreated, unlike TB at the advanced stage.

21In the context of HIV infection, comparative studies of TB and histoplasmosis found that whilst many similar features are noted in the two infections, with most reports detailing information on disseminated Hcc infection, there are also some distinguishing features (Table 3). In the HIV/AIDS context, disseminated histoplasmosis is usual, often with some pulmonary involvement, but other clinical features are more prominent, notably diarrhoea or other gastrointestinal symptoms, skin lesions, and pancytopenia, which vary in different regions. Coinfection of TB and histoplasmosis has been documented in 8% to 15% of cases. Other features include reticulonodular lesions, multiple pulmonary nodules, hilar and mediastinal adenopathy, and progressive fibrosis.

22Culture is potentially hazardous for laboratory personnel and requires a level 3 biosafety facility (which is not available in most African countries). It remains the reference method for disseminated histoplasmosis, particularly in HIV-infected patients, although growth requires a one- to six-week incubation, resulting in delay of treatment initiation. Though specificity of the culture method is 100%, sensitivity depends on the fungal load. Bone marrow aspirates yield the highest proportion of positive cultures (70%–90%). Culture is not very useful in diagnosing primary infections in immunocompetent patients with low fungal load. In disseminated cases, blood cultures using the centrifugation–lysis system or automated blood culture systems have increased sensitivity.

23Bone marrow biopsy for histopathology is a rapid method of establishing a definitive diagnosis of disseminated histoplasmosis. However, this method lacks sensitivity for subacute and chronic forms of the pulmonary histoplasmosis. Another challenge with histology is that the morphology of the H. capsulatum yeasts is very similar to other pathogens, and these characteristics can lead to a mistake in identification. Misidentification occurs principally with Candida glabrata, Talaromyces marneffei, Pneumocystis jirovecii, Toxoplasma gondii, Leishmania donovani, and Cryptococcus neoformans.

24Serology for anti-Histoplasma antibodies is particularly useful in cases of low fungal load, as in asymptomatic or chronic pulmonary histoplasmosis. Antibody detection by immunodiffusion or complement fixation is less sensitive in immunocompromised HIV-infected patients than in immunocompetent patients. The rise of antibody titres is usually observed two to six weeks after primary exposure. Antibody testing of cerebrospinal fluid (CSF) is critical for suspected cases of neuromeningeal histoplasmosis. Cross-reactions with other fungal pathogens, lymphoma, sarcoidosis, and TB have been reported. A recent study from Brazil using a western blot test strip found a sensitivity of 94.9%, specificity of 94.1%, positive predictive value (PPV) 94.1%, negative predictive value (NPV) 94.9%, and almost perfect precision. Another recent study demonstrated that the Miravista Histoplasma antibody enzyme immunoassay (EIA) offers increased sensitivity over other current antibody tests and detects both immunoglobulin G (IgG) and IgM antibodies and complements antigen detection. Therefore, combining antigen and EIA antibody testing provides an optimal method for diagnosis of acute pulmonary histoplasmosis.

25Diagnosing disseminated histoplasmosis has been significantly facilitated by the development of Histoplasma antigen testing. The detection of Hcc circulating antigen has been performed using several EIA methods. Antigen testing of blood or urine in disseminated histoplasmosis is most sensitive in immunocompromised patients and those with more severe illness, with higher titres. The antigen level correlates with the severity of the disease. Histoplasma antigen cross-reacts in sporotrichosis, aspergillosis (10%), coccidioidomycosis (60%), paracoccidioidomycosis (80%), and blastomycosis (90%). In spite of this, Histoplasma antigen testing still remains the mainstay of diagnosing histoplasmosis in immunocompromised patients. There is no cross-reactivity between C. neoformans and Histoplasma antigen.

26Molecular methods have been reported for the diagnosis of histoplasmosis with inconsistent accuracy. No single approach based on nucleic acid amplification assays has been established as the dominant method; Histoplasma can be detected in tissue biopsies and whole blood, but these methods are not sensitive enough to identify Histoplasma in urine or serum.

27In most of the reported cases from Africa, the diagnosis was made by culture and histology; only in five countries (Tanzania, Benin, South Africa, Egypt, and Uganda) was serology reported as being used to make a diagnosis, and in three of the cases, the samples were processed in Western countries.

28The Infectious Diseases Society of America recommends prophylaxis with itraconazole for as long as the CD4 count remains below 150/mm3 in highly endemic areas with an incidence of histoplasmosis of >10 cases per 100 person-years. If efavirenz and itraconazole are given together, itraconazole levels fall by 40%, so higher doses are required.

29While waiting for laboratory confirmation of histoplasmosis in a patient with a strong suspicion of histoplasmosis with or without severe symptoms, physicians have the following two choices for treatment induction: intravenous (IV) amphotericin B or oral itraconazole. Although amphotericin B is usually fungicidal and has shown its efficacy in terms of survival, it is also nephrotoxic. Liposomal amphotericin is superior to conventional amphotericin B for disseminated histoplasmosis in AIDS. Itraconazole is also fungicidal for most isolates of H. capsulatum, but oral capsules are not always well absorbed in advanced AIDS, and it is associated with many drug–drug interactions, including rifampicin. For these reasons, amphotericin B is preferred for initial therapy of disseminated histoplasmosis in AIDS, but itraconazole is a good choice for subacute disseminated infection.

30Worryingly, amphotericin B is not licensed and is unavailable in a number of African countries; even where it is available, the cost may be prohibitive. Liposomal amphotericin B is excessively costly and not available in most of Africa. While available in most African countries, itraconazole is prohibitively costly in most. Generic formulations are available, but varying quality is a challenge.

31Clinical outcomes were variable in the African studies reviewed and depended on a number of factors, such as the type of disease, early/prompt diagnosis, and accessibility to the effective drugs. Most cases of cutaneous lesions and disseminated diseases resolve with amphotericin B and itraconazole, while response to ketoconazole was variable and often poor. Loulerge and colleagues reported good responses (>50%) and cure in disseminated HIV-positive cases mainly with amphotericin B and high-dose itraconazole. In cases with HIV, outcomes were complicated by other comorbidities associated with immune suppression. In AIDS patients in the US, histoplasmosis-related mortality was around 10% during the HAART era.

32In conclusion, histoplasmosis is a neglected disease in Africa, a continent that has a significant number of people living with HIV/AIDS. Under-recognition and under-diagnosis are major challenges attributable to the lack of skilled personnel and facilities to make this diagnosis. It is imperative that concerted efforts be made in tackling this. It is also important for physicians outside of endemic regions to recognise this disease and how to manage it. This is particularly important in view of migratory patterns of Africans.

33Histoplasmosis is a neglected disease in Africa. This is because histoplasmosis in Africa has markedly increased but is under-recognised.

34Histoplasmosis may be misdiagnosed as TB.

35Africa has a significant number of people living with HIV/AIDS, which is the greatest attributable risk factor for histoplasmosis.

36The ongoing health agenda for Africa must acknowledge the lack of skilled personnel and facilities to make the diagnosis of histoplasmosis in Africa.

37There is limited accessibility and availability of antifungal agents on the African continent.

38Wheat LJ. Histoplasmosis: A review for clinicians from non-endemic areas. Mycoses. 2006;49(4):274–82.

39Hage CA, Ribes JA, Wengenack NL, Baddour LM, Assi M, McKinsey DS, et al. A Multicenter Evaluation of Tests for Diagnosis of Histoplasmosis. Clin Infect Dis 2011;53(5):448–54

40Antinori S, Magni C, Nebuloni M, Parravicini C, Corbellino M, Sollima S, et al. Histoplasmosis Among Human Immunodeficiency Virus-Infected People in Europe. Medicine (Baltimore) 2006;85(1):22–36.

41Kneale M, Bartholomew JS, Davies E, Denning DW. Global access to antifungal therapy and its variable cost. J Antimicrob Chemother 2016;71(12):3599–606.

42Valero C, Gago S, Monteiro MC, Buitrago MJ. African histoplasmosis: new clinical and microbiological insights. 2017; Med Mycol. 2018;56(1):51-59. doi: 10.1093/mmy/myx020